EMA gives thumbs up to Vanda sleep disorder drug; Zynga names ex-Genentech CFO to its board;

@FiercePharma: Labeling foul-up involving acetaminophen leads RB to recall 135 lots of Mucinex. News | Follow @FiercePharma

@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Watch out, Big Pharma: A Teva-Mylan combo would remake the industry Top 10. Story | Follow @CarlyHFierce

> Vanda Pharmaceuticals ($VNDA) drug Helioz has been recommended for approval in Europe to treat non-24-hour sleep-wake disorder in totally blind adults. Release

> The European Medicines Agency, like the FDA, has found there is a risk of severe bradycardia or heart block problems when Gilead Sciences' ($GILD) hep C combo drug Harvoni is taken by patients who also are on amiodarone for treating an irregular heartbeat. Release

> Mobile game maker Zynga has added former Genetech CFO Louis Lavigne to its board. Release

Medical Device News

@FierceMedDev: Low-cost smart syringe shoots for reduced disease transmission. News | Follow @FierceMedDev

@VarunSaxena2: Ahead of Apple Watch launch, hearing aid company reveals its app development experience. Story | Follow @VarunSaxena2

@EmilyWFierce: Medical device makers such as $GE, $ABT, $BSX and $JNJ forming the first industry trade group in #Asia. Pharmalot story | Follow @EmilyWFierce

> Bard's Lutonix drug-coated balloons help lift Q1 earnings. News

> FDA deems all 4,000+ of troubled Maquet's left atrial appendage closure devices potentially deadly, announces major recall. More

Biotech News

@FierceBiotech: AstraZeneca loans its oncology star to Celgene, recruits Innate in a PD-L1 deal spree. News | Follow @FierceBiotech

@JohnCFierce: Aerie shares crushed after glaucoma therapy flops in PhIII. Story | Follow @JohnCFierce

> Biogen blueprints a big Phase III effort for its Alzheimer's hopeful. Article

> Regeneron, Alnylam help drive a $2B spike in biotech R&D spending. More

> Sanofi dumps an ImmunoGen cancer drug as it scales back in oncology. News

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.